Contact Us
Contact Us
Contact Us


Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements

28/01/2020Appendix 3BDownload
28/01/2020Clarification AnnouncementDownload
28/01/2020Prof Borje Andersson appointed as Non-Executive DirectorDownload
14/01/2020Notification of Expiry of Unlisted OptionsDownload
13/01/2020Australian Clinical Trials Manager to replace European RoleDownload
1  2  3  4  



Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2020 Race Oncology. Website By Multiplier